N/A
Completed N=200
Social Forces to Improve Statin Adherence (Study A)
Medication Adherence · High Blood Pressure · Diabetes
Source: ClinicalTrials.gov NCT02018809 ↗
Enrolled (actual)
200
Serious AEs
0.0%
Results posted
May 2017
Primary outcomePrimary: Statin Adherence — 86; 85; 86; 85 percentage of correct statin doses
Summary
To assess the effectiveness of reporting statin adherence patterns to a Medication Adherence Partner (MAP) in improving the outcome of statin adherence versus usual care as measured by an electronic pill bottle.
Hypothesis: Subjects with a MAP receiving daily adherence feedback will have the highest statin adherence of any arm, as measured by pill bottle data.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Statin Adherence |
86; 85; 86; 85 | — |
| SECONDARY Morisky Medication Adherence Scale (MMAS) |
5.38; 6; 5.75; 5.75 | — |
Eligibility Criteria
Inclusion Criteria
- The subject is Humana insured
- The subject is an English speaking adult
- Age range ≥18 years
- The subject has diagnosis with diabetes for ≥12 months
- The subject has an MPR <70% to a statin medication
- Subject denies side-effects to their statin medication
- The subject identified a person who agreed to serve as their MAP
Exclusion Criteria
- The subject is <18 years old
- The subject is considered part of a vulnerable population (is a prisoner, a cognitively impaired person, or a pregnant woman)
- On statin combination medication
- The subject does not identify an individual who agrees to serve as their MAP
- The subject reports a clinically important side effect to the statin medication or active liver disease:
Data sourced from ClinicalTrials.gov (NCT02018809). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.